Alliance for the Prudent Use of Antibiotics
The mission of the Alliance for the Prudent Use of Antibiotics (APUA) is to strengthen global defenses against infectious disease by ensuring access to effective treatment and promoting appropriate antibiotic use to contain drug resistance. With a network of affiliated chapters in 19 countries, APUA stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.
- APUA testifies before Canadian House of Commons
- APUA supports restored congressional funding for AMR
- APUA - Nepal Newsletter issued
- Uruguay reactivates chapter; new publication issued
- National "AMR action plans" now prevalent
- WHO guidelines call for end to routine antibiotics in farm animals
- EU defines indicators for assessing antimicrobial consumption and antimicrobial resistance (AMR)
- WHO releases guidelines for preventing carbapenem-resistanct infections
- International Call to Action aims to galvanize momentum; fill gaps
- PAVE award aims to spur development of new antimicrobials
- Hong Kong adopts action plan for addressing AMR
- New Guidelines issued for infection prevention in young athletes
- The antibiotic pipeline: what lies ahead?
- Closthioamide - a new class of antibiotic for gonorrhea?
- Nitric oxide emerges as new superbug therapy
- Mushrooms viewed as untapped source of new antimicrobials
- Bacteriocins find practical applications in targeting resistant pathogenns
- Pre-op antibiotics cleared for low risk surgeries
- Benefits of stewardship interventions diminish over time, but "peer-comparison" remains durable
- Ampicillin resistance may have emerged from early penicillin use in livestock
- EU survey finds increasing livestock-associated MRSA (LA-MRSA) among humans
- Antibiotic side effects: new worries over IBD and infant gut microbiomes
- Skin microbiome negatively impacted by antimicrobials
- UK calculates drop in lifeapan due to AMR
- Inappropriate dental use of antibiotics may be increasing C. difficile infection
- FDA issues new guidelines to ensure safer, less contaminated mattresses
- Wireless "electric bandage" disrupts stubborn biofilms
- Study shows four simple tests can help identify pneumonia and reduce antibiotic use
- Events and publications of interest
APUA WELCOMES NEW BOARD MEMBERS
APUA is proud to announce the addition of five new members to our Board of Directors:
- Robert Gaynes, MD, Professor - Department of Medicine - Emory School of Medicine
- Shahin Gharakhanian, MD - Cambridge Innovation Center
- Cristina Larkin, Chief Commercial Officer - Spero Therapeutics
- Margaret Riley, PhD, Professor - Department of Biology - University of Massachusetts, Amherst
- David White, PhD, Associate Dean of Research - University of Tennessee School of Agriculture
You can view the complete list of APUA Board members
APUA extends its deepest thanks to Dennis Signorovitch as he completes 10 years of outstanding service as a member of APUA's Board of Directors. His leadership, advice and enthusiasm have aided the organization immeasurably in forwarding its mission and we wish him well in all his future endeavors. Thank you, Dennis!
"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment. Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."
Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine
From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)
In case you missed it, our latest webinar
is now available for streaming